Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial

Wei Jiang, David J. Whellan, Kirkwood F. Adams, Michael A. Babyak, Stephen H. Boyle, Jennifer L. Wilson, Chetan B. Patel, Joseph G. Rogers, William Harris, Christopher M. O'Connor

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives: The goal of this study was to test the effects of long-chain omega-3 fatty acid supplementation on omega-3 levels, depressive symptoms, and other psychosocial factors, as well as other chronic heart failure (CHF)-related functional measures. Background: Patients with CHF and depression had low blood omega-3 concentrations that were associated with an elevated risk of mortality. Methods: This study was a randomized, double-blind, placebo-controlled pilot clinical trial using a 400/200 eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) fish oil at 2 g and an almost pure EPA at 2 g, compared with a matched placebo, daily for 12 weeks for patients with CHF and major depressive disorder. Statistical analyses included the intention-to-treat population and “completers” (defined as participants consuming ≥70% of the capsules and completing the final endpoint evaluation between 10 and 14 weeks). Results: A total of 108 patients with CHF and major depressive disorder and a score ≥18 on the Hamilton Depression Scale who were randomized at 1:1:1 to the 3 interventions at 3 enrolling centers from June 12, 2014, to May 19, 2016; 80 (74.1%) qualified as completers. Intention-to-treat analyses revealed that the levels of all omega-3 variables were significantly elevated in the omega-3 groups, whereas the placebo group showed little change; there were no between-group differences with overall depression measurements. Per-protocol exploratory analyses showed that scores on the social functioning measurement of the 36-item Short Form Health Survey improved notably in the 400/200 EPA/DHA (p = 0.040) and EPA (p = 0.10) groups compared with the placebo group. Spearman correlation analysis indicated that increased omega-3 indices were associated with improved cognitive depressive symptoms. Conclusions: Omega-3 supplementation resulted in significant increases in omega-3 levels in red blood cell counts, corresponding to a particular compound of omega-3. Changes in cognitive depressive symptoms and social function were in favor of the omega-3 supplementation. Further studies with larger sample sizes are necessary to confirm the benefits of omega-3 supplementation on modifying psychosocial factors for patients with CHF. (Omega-3 Supplementation for Co-Morbid Depression and Heart Failure Treatment [OCEAN]; NCT02057406)

Original languageEnglish (US)
Pages (from-to)833-843
Number of pages11
JournalJACC: Heart Failure
Volume6
Issue number10
DOIs
StatePublished - Oct 1 2018
Externally publishedYes

Fingerprint

Omega-3 Fatty Acids
Heart Failure
Depression
Eicosapentaenoic Acid
Placebos
Neurobehavioral Manifestations
Intention to Treat Analysis
Docosahexaenoic Acids
Major Depressive Disorder
Psychology
Erythrocyte Count
Fish Oils
Controlled Clinical Trials
Health Surveys
Sample Size
Capsules
Mortality
Population

Keywords

  • congestive heart failure
  • long-chain omega-3 fatty acids
  • major depressive disorder

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Jiang, W., Whellan, D. J., Adams, K. F., Babyak, M. A., Boyle, S. H., Wilson, J. L., ... O'Connor, C. M. (2018). Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial. JACC: Heart Failure, 6(10), 833-843. https://doi.org/10.1016/j.jchf.2018.03.011

Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients : Results of the OCEAN Trial. / Jiang, Wei; Whellan, David J.; Adams, Kirkwood F.; Babyak, Michael A.; Boyle, Stephen H.; Wilson, Jennifer L.; Patel, Chetan B.; Rogers, Joseph G.; Harris, William; O'Connor, Christopher M.

In: JACC: Heart Failure, Vol. 6, No. 10, 01.10.2018, p. 833-843.

Research output: Contribution to journalArticle

Jiang, W, Whellan, DJ, Adams, KF, Babyak, MA, Boyle, SH, Wilson, JL, Patel, CB, Rogers, JG, Harris, W & O'Connor, CM 2018, 'Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial', JACC: Heart Failure, vol. 6, no. 10, pp. 833-843. https://doi.org/10.1016/j.jchf.2018.03.011
Jiang, Wei ; Whellan, David J. ; Adams, Kirkwood F. ; Babyak, Michael A. ; Boyle, Stephen H. ; Wilson, Jennifer L. ; Patel, Chetan B. ; Rogers, Joseph G. ; Harris, William ; O'Connor, Christopher M. / Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients : Results of the OCEAN Trial. In: JACC: Heart Failure. 2018 ; Vol. 6, No. 10. pp. 833-843.
@article{5e7655d2ed2b401c8474b35db4192cc4,
title = "Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial",
abstract = "Objectives: The goal of this study was to test the effects of long-chain omega-3 fatty acid supplementation on omega-3 levels, depressive symptoms, and other psychosocial factors, as well as other chronic heart failure (CHF)-related functional measures. Background: Patients with CHF and depression had low blood omega-3 concentrations that were associated with an elevated risk of mortality. Methods: This study was a randomized, double-blind, placebo-controlled pilot clinical trial using a 400/200 eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) fish oil at 2 g and an almost pure EPA at 2 g, compared with a matched placebo, daily for 12 weeks for patients with CHF and major depressive disorder. Statistical analyses included the intention-to-treat population and “completers” (defined as participants consuming ≥70{\%} of the capsules and completing the final endpoint evaluation between 10 and 14 weeks). Results: A total of 108 patients with CHF and major depressive disorder and a score ≥18 on the Hamilton Depression Scale who were randomized at 1:1:1 to the 3 interventions at 3 enrolling centers from June 12, 2014, to May 19, 2016; 80 (74.1{\%}) qualified as completers. Intention-to-treat analyses revealed that the levels of all omega-3 variables were significantly elevated in the omega-3 groups, whereas the placebo group showed little change; there were no between-group differences with overall depression measurements. Per-protocol exploratory analyses showed that scores on the social functioning measurement of the 36-item Short Form Health Survey improved notably in the 400/200 EPA/DHA (p = 0.040) and EPA (p = 0.10) groups compared with the placebo group. Spearman correlation analysis indicated that increased omega-3 indices were associated with improved cognitive depressive symptoms. Conclusions: Omega-3 supplementation resulted in significant increases in omega-3 levels in red blood cell counts, corresponding to a particular compound of omega-3. Changes in cognitive depressive symptoms and social function were in favor of the omega-3 supplementation. Further studies with larger sample sizes are necessary to confirm the benefits of omega-3 supplementation on modifying psychosocial factors for patients with CHF. (Omega-3 Supplementation for Co-Morbid Depression and Heart Failure Treatment [OCEAN]; NCT02057406)",
keywords = "congestive heart failure, long-chain omega-3 fatty acids, major depressive disorder",
author = "Wei Jiang and Whellan, {David J.} and Adams, {Kirkwood F.} and Babyak, {Michael A.} and Boyle, {Stephen H.} and Wilson, {Jennifer L.} and Patel, {Chetan B.} and Rogers, {Joseph G.} and William Harris and O'Connor, {Christopher M.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.jchf.2018.03.011",
language = "English (US)",
volume = "6",
pages = "833--843",
journal = "JACC: Heart Failure",
issn = "2213-1779",
publisher = "Elsevier BV",
number = "10",

}

TY - JOUR

T1 - Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients

T2 - Results of the OCEAN Trial

AU - Jiang, Wei

AU - Whellan, David J.

AU - Adams, Kirkwood F.

AU - Babyak, Michael A.

AU - Boyle, Stephen H.

AU - Wilson, Jennifer L.

AU - Patel, Chetan B.

AU - Rogers, Joseph G.

AU - Harris, William

AU - O'Connor, Christopher M.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Objectives: The goal of this study was to test the effects of long-chain omega-3 fatty acid supplementation on omega-3 levels, depressive symptoms, and other psychosocial factors, as well as other chronic heart failure (CHF)-related functional measures. Background: Patients with CHF and depression had low blood omega-3 concentrations that were associated with an elevated risk of mortality. Methods: This study was a randomized, double-blind, placebo-controlled pilot clinical trial using a 400/200 eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) fish oil at 2 g and an almost pure EPA at 2 g, compared with a matched placebo, daily for 12 weeks for patients with CHF and major depressive disorder. Statistical analyses included the intention-to-treat population and “completers” (defined as participants consuming ≥70% of the capsules and completing the final endpoint evaluation between 10 and 14 weeks). Results: A total of 108 patients with CHF and major depressive disorder and a score ≥18 on the Hamilton Depression Scale who were randomized at 1:1:1 to the 3 interventions at 3 enrolling centers from June 12, 2014, to May 19, 2016; 80 (74.1%) qualified as completers. Intention-to-treat analyses revealed that the levels of all omega-3 variables were significantly elevated in the omega-3 groups, whereas the placebo group showed little change; there were no between-group differences with overall depression measurements. Per-protocol exploratory analyses showed that scores on the social functioning measurement of the 36-item Short Form Health Survey improved notably in the 400/200 EPA/DHA (p = 0.040) and EPA (p = 0.10) groups compared with the placebo group. Spearman correlation analysis indicated that increased omega-3 indices were associated with improved cognitive depressive symptoms. Conclusions: Omega-3 supplementation resulted in significant increases in omega-3 levels in red blood cell counts, corresponding to a particular compound of omega-3. Changes in cognitive depressive symptoms and social function were in favor of the omega-3 supplementation. Further studies with larger sample sizes are necessary to confirm the benefits of omega-3 supplementation on modifying psychosocial factors for patients with CHF. (Omega-3 Supplementation for Co-Morbid Depression and Heart Failure Treatment [OCEAN]; NCT02057406)

AB - Objectives: The goal of this study was to test the effects of long-chain omega-3 fatty acid supplementation on omega-3 levels, depressive symptoms, and other psychosocial factors, as well as other chronic heart failure (CHF)-related functional measures. Background: Patients with CHF and depression had low blood omega-3 concentrations that were associated with an elevated risk of mortality. Methods: This study was a randomized, double-blind, placebo-controlled pilot clinical trial using a 400/200 eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) fish oil at 2 g and an almost pure EPA at 2 g, compared with a matched placebo, daily for 12 weeks for patients with CHF and major depressive disorder. Statistical analyses included the intention-to-treat population and “completers” (defined as participants consuming ≥70% of the capsules and completing the final endpoint evaluation between 10 and 14 weeks). Results: A total of 108 patients with CHF and major depressive disorder and a score ≥18 on the Hamilton Depression Scale who were randomized at 1:1:1 to the 3 interventions at 3 enrolling centers from June 12, 2014, to May 19, 2016; 80 (74.1%) qualified as completers. Intention-to-treat analyses revealed that the levels of all omega-3 variables were significantly elevated in the omega-3 groups, whereas the placebo group showed little change; there were no between-group differences with overall depression measurements. Per-protocol exploratory analyses showed that scores on the social functioning measurement of the 36-item Short Form Health Survey improved notably in the 400/200 EPA/DHA (p = 0.040) and EPA (p = 0.10) groups compared with the placebo group. Spearman correlation analysis indicated that increased omega-3 indices were associated with improved cognitive depressive symptoms. Conclusions: Omega-3 supplementation resulted in significant increases in omega-3 levels in red blood cell counts, corresponding to a particular compound of omega-3. Changes in cognitive depressive symptoms and social function were in favor of the omega-3 supplementation. Further studies with larger sample sizes are necessary to confirm the benefits of omega-3 supplementation on modifying psychosocial factors for patients with CHF. (Omega-3 Supplementation for Co-Morbid Depression and Heart Failure Treatment [OCEAN]; NCT02057406)

KW - congestive heart failure

KW - long-chain omega-3 fatty acids

KW - major depressive disorder

UR - http://www.scopus.com/inward/record.url?scp=85053370920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053370920&partnerID=8YFLogxK

U2 - 10.1016/j.jchf.2018.03.011

DO - 10.1016/j.jchf.2018.03.011

M3 - Article

AN - SCOPUS:85053370920

VL - 6

SP - 833

EP - 843

JO - JACC: Heart Failure

JF - JACC: Heart Failure

SN - 2213-1779

IS - 10

ER -